Nanjing Pharma Launches $110M Corporate Fund to Acquire Controlling Stakes in Datsing Bio and Kejian Tech
Nanjing Pharmaceutical Group Co., Ltd. (SHA: 600713) has unveiled a strategic plan to establish a...
SHA: 600713
Nanjing Pharmaceutical to Acquire Majority Stakes in Three Jiangsu Subsidiaries
China-based Shanghai-listed Nanjing Pharmaceutical Co., Ltd (SHA: 600713) is set to acquire a respective 55%,...